UNSPSC 51363304: Rogletimide

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 14P4QR28QF, chemically known as 2,6-piperidinedione, 3-ethyl-3-(4-pyridinyl)- but generally known as rogletimide, which bears US NIH Compound Identifier 56487. European Medicines Agency schedules Rogletimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10360MIG.

UNSPSC 51363304 Rogletimide, a Commodity code, shows limited alignment between the code's nominal scope and recent state and local procurement activity. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—solicits naloxone and safe drug deactivation systems, neither of which corresponds to rogletimide, a pharmaceutical compound. The county seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs in their proposals, provide unit pricing for each line item, maintain workers' compensation and commercial general liability insurance, comply with E-Verify requirements, and hold a drug-free workplace certification. The contract carries an initial two-year term with a one-year renewal option and includes a three-month probationary period allowing termination by the county with or without cause. The procurement may be federally funded through FEMA, introducing Clean Air Act and Federal Water Pollution Control Act compliance obligations.

Activity under this code remains sparse and geographically narrow. The Seminole County opportunity represents the only recent state or local solicitation on record. The IFB response deadline was July 26, 2023—substantially prior to the current date—indicating no active bidding window. The mismatch between the code's pharmaceutical designation and the actual procurement (which targets public-health harm-reduction equipment rather than a rogletimide therapeutic product) suggests the code may have been misapplied in the state or local procurement system or represents a data error. Business development professionals should verify current activity outside this record and confirm whether state and local buyers actually procure rogletimide under this or a related code before building pipeline activity.